AbbVie's hepatitis C regimen wins breakthrough designation from FDA

05/7/2013 | Chicago Tribune (tiered subscription model) · RTT News

The FDA granted breakthrough therapy status to AbbVie's experimental direct-acting antiviral regimen, with and without ribavirin, as a therapy for genotype 1 hepatitis C virus. The combo is in late-stage trials in 29 nations.

View Full Article in:

Chicago Tribune (tiered subscription model) · RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
Boise, ID